Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer: Mechanisms and therapeutic implications

Ching-Hsien Chen, Sarah Statt, Chun Lung Chiu, Philip Thai, Muhammad Arif, Kenneth B. Adler, Reen Wu

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Rationale: Phosphorylation of myristoylated alanine-rich C kinase substrate (phospho-MARCKS) at the phosphorylation site domain (PSD) is crucial for mucus granule secretion and cell motility, but little is known concerning its function in lung cancer. Objectives: We aimed to determine if MARCKS PSD activity can serve as a therapeutic target and to elucidate the molecular basis of this potential. Methods: The clinical relevance of phospho-MARCKS was first confirmed. Next, we used genetic approaches to verify the functionality and molecular mechanism of phospho-MARCKS. Finally, cancer cells were pharmacologically inhibited for MARCKS activity and subjected to functional bioassays. Measurements and Main Results: We demonstrated that higher phospho-MARCKS levels were correlated with shorter overall survival of lung cancer patients. Using shRNA silencing and ectopic expression of wild-type and PSD-mutated (S159/163A) MARCKS, we showed that elevated phospho-MARCKS promoted cancer growth and erlotinib resistance. Further studies demonstrated an interaction of phosphoinositide 3-kinase with MARCKS, but not with phospho-MARCKS. Interestingly, phospho-MARCKS acted in parallel with increased phosphatidylinositol (3,4,5)-triphosphate pools and AKT activation in cells. Through treatment with a 25-mer peptide targeting the MARCKS PSD motif (MPS peptide), we were able to suppress tumor growth and metastasis in vivo, and reduced levels of phospho-MARCKS, phosphatidylinositol (3,4,5)-triphosphate, and AKT activity. This peptide also enhanced the sensitivity of lung cancer cells to erlotinib treatment, especially those with sustained activation of phosphoinositide 3-kinase/AKT signaling. Conclusions: These results suggest a key role for MARCKS PSD in cancer disease and provide a unique strategy for inhibiting the activity of MARCKS PSD as a treatment for lung cancer.

Original languageEnglish (US)
Pages (from-to)1127-1138
Number of pages12
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume190
Issue number10
DOIs
StatePublished - Nov 15 2014

Fingerprint

Lung Neoplasms
Phosphorylation
1-Phosphatidylinositol 4-Kinase
Peptides
Therapeutics
Neoplasms
Mucus
Growth
myristoylated alanine-rich C kinase substrate
Biological Assay
Small Interfering RNA
Cell Movement
Neoplasm Metastasis
Survival

Keywords

  • Erlotinib
  • Lung cancer
  • MARCKS phosphorylation
  • PI3K/AKT
  • PIP3

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer : Mechanisms and therapeutic implications. / Chen, Ching-Hsien; Statt, Sarah; Chiu, Chun Lung; Thai, Philip; Arif, Muhammad; Adler, Kenneth B.; Wu, Reen.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 190, No. 10, 15.11.2014, p. 1127-1138.

Research output: Contribution to journalArticle

@article{2b19213501914ed0a3e4cd9ea2aa0a14,
title = "Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer: Mechanisms and therapeutic implications",
abstract = "Rationale: Phosphorylation of myristoylated alanine-rich C kinase substrate (phospho-MARCKS) at the phosphorylation site domain (PSD) is crucial for mucus granule secretion and cell motility, but little is known concerning its function in lung cancer. Objectives: We aimed to determine if MARCKS PSD activity can serve as a therapeutic target and to elucidate the molecular basis of this potential. Methods: The clinical relevance of phospho-MARCKS was first confirmed. Next, we used genetic approaches to verify the functionality and molecular mechanism of phospho-MARCKS. Finally, cancer cells were pharmacologically inhibited for MARCKS activity and subjected to functional bioassays. Measurements and Main Results: We demonstrated that higher phospho-MARCKS levels were correlated with shorter overall survival of lung cancer patients. Using shRNA silencing and ectopic expression of wild-type and PSD-mutated (S159/163A) MARCKS, we showed that elevated phospho-MARCKS promoted cancer growth and erlotinib resistance. Further studies demonstrated an interaction of phosphoinositide 3-kinase with MARCKS, but not with phospho-MARCKS. Interestingly, phospho-MARCKS acted in parallel with increased phosphatidylinositol (3,4,5)-triphosphate pools and AKT activation in cells. Through treatment with a 25-mer peptide targeting the MARCKS PSD motif (MPS peptide), we were able to suppress tumor growth and metastasis in vivo, and reduced levels of phospho-MARCKS, phosphatidylinositol (3,4,5)-triphosphate, and AKT activity. This peptide also enhanced the sensitivity of lung cancer cells to erlotinib treatment, especially those with sustained activation of phosphoinositide 3-kinase/AKT signaling. Conclusions: These results suggest a key role for MARCKS PSD in cancer disease and provide a unique strategy for inhibiting the activity of MARCKS PSD as a treatment for lung cancer.",
keywords = "Erlotinib, Lung cancer, MARCKS phosphorylation, PI3K/AKT, PIP3",
author = "Ching-Hsien Chen and Sarah Statt and Chiu, {Chun Lung} and Philip Thai and Muhammad Arif and Adler, {Kenneth B.} and Reen Wu",
year = "2014",
month = "11",
day = "15",
doi = "10.1164/rccm.201408-1505OC",
language = "English (US)",
volume = "190",
pages = "1127--1138",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer

T2 - Mechanisms and therapeutic implications

AU - Chen, Ching-Hsien

AU - Statt, Sarah

AU - Chiu, Chun Lung

AU - Thai, Philip

AU - Arif, Muhammad

AU - Adler, Kenneth B.

AU - Wu, Reen

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Rationale: Phosphorylation of myristoylated alanine-rich C kinase substrate (phospho-MARCKS) at the phosphorylation site domain (PSD) is crucial for mucus granule secretion and cell motility, but little is known concerning its function in lung cancer. Objectives: We aimed to determine if MARCKS PSD activity can serve as a therapeutic target and to elucidate the molecular basis of this potential. Methods: The clinical relevance of phospho-MARCKS was first confirmed. Next, we used genetic approaches to verify the functionality and molecular mechanism of phospho-MARCKS. Finally, cancer cells were pharmacologically inhibited for MARCKS activity and subjected to functional bioassays. Measurements and Main Results: We demonstrated that higher phospho-MARCKS levels were correlated with shorter overall survival of lung cancer patients. Using shRNA silencing and ectopic expression of wild-type and PSD-mutated (S159/163A) MARCKS, we showed that elevated phospho-MARCKS promoted cancer growth and erlotinib resistance. Further studies demonstrated an interaction of phosphoinositide 3-kinase with MARCKS, but not with phospho-MARCKS. Interestingly, phospho-MARCKS acted in parallel with increased phosphatidylinositol (3,4,5)-triphosphate pools and AKT activation in cells. Through treatment with a 25-mer peptide targeting the MARCKS PSD motif (MPS peptide), we were able to suppress tumor growth and metastasis in vivo, and reduced levels of phospho-MARCKS, phosphatidylinositol (3,4,5)-triphosphate, and AKT activity. This peptide also enhanced the sensitivity of lung cancer cells to erlotinib treatment, especially those with sustained activation of phosphoinositide 3-kinase/AKT signaling. Conclusions: These results suggest a key role for MARCKS PSD in cancer disease and provide a unique strategy for inhibiting the activity of MARCKS PSD as a treatment for lung cancer.

AB - Rationale: Phosphorylation of myristoylated alanine-rich C kinase substrate (phospho-MARCKS) at the phosphorylation site domain (PSD) is crucial for mucus granule secretion and cell motility, but little is known concerning its function in lung cancer. Objectives: We aimed to determine if MARCKS PSD activity can serve as a therapeutic target and to elucidate the molecular basis of this potential. Methods: The clinical relevance of phospho-MARCKS was first confirmed. Next, we used genetic approaches to verify the functionality and molecular mechanism of phospho-MARCKS. Finally, cancer cells were pharmacologically inhibited for MARCKS activity and subjected to functional bioassays. Measurements and Main Results: We demonstrated that higher phospho-MARCKS levels were correlated with shorter overall survival of lung cancer patients. Using shRNA silencing and ectopic expression of wild-type and PSD-mutated (S159/163A) MARCKS, we showed that elevated phospho-MARCKS promoted cancer growth and erlotinib resistance. Further studies demonstrated an interaction of phosphoinositide 3-kinase with MARCKS, but not with phospho-MARCKS. Interestingly, phospho-MARCKS acted in parallel with increased phosphatidylinositol (3,4,5)-triphosphate pools and AKT activation in cells. Through treatment with a 25-mer peptide targeting the MARCKS PSD motif (MPS peptide), we were able to suppress tumor growth and metastasis in vivo, and reduced levels of phospho-MARCKS, phosphatidylinositol (3,4,5)-triphosphate, and AKT activity. This peptide also enhanced the sensitivity of lung cancer cells to erlotinib treatment, especially those with sustained activation of phosphoinositide 3-kinase/AKT signaling. Conclusions: These results suggest a key role for MARCKS PSD in cancer disease and provide a unique strategy for inhibiting the activity of MARCKS PSD as a treatment for lung cancer.

KW - Erlotinib

KW - Lung cancer

KW - MARCKS phosphorylation

KW - PI3K/AKT

KW - PIP3

UR - http://www.scopus.com/inward/record.url?scp=84922987353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922987353&partnerID=8YFLogxK

U2 - 10.1164/rccm.201408-1505OC

DO - 10.1164/rccm.201408-1505OC

M3 - Article

C2 - 25318062

AN - SCOPUS:84922987353

VL - 190

SP - 1127

EP - 1138

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -